Silverback Therapeutics Inc. (SBTX): Price and Financial Metrics
SBTX Price/Volume Stats
Current price | $5.87 | 52-week high | $8.97 |
Prev. close | $5.81 | 52-week low | $2.80 |
Day low | $5.72 | Volume | 116,700 |
Day high | $6.15 | Avg. volume | 337,931 |
50-day MA | $5.39 | Dividend yield | N/A |
200-day MA | $4.38 | Market Cap | 211.66M |
SBTX Stock Price Chart Interactive Chart >
Silverback Therapeutics Inc. (SBTX) Company Bio
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
SBTX Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | -19.81% |
5-year | N/A |
YTD | N/A |
2023 | N/A |
2022 | 0.00% |
2021 | -85.63% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...